We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting

By LabMedica International staff writers
Posted on 29 Jul 2014
The 2014 American Association of Clinical Chemistry (AACC; Washington DC, USA) annual meeting & clinical lab expo, which is taking place in Chicago (IL, USA) from July 27-31, 2014, focuses on mobile health, big data, and antimicrobial resistance, among many other major healthcare topics.

The meeting and clinical expo is expected to draw more than 17,500 attendees, including prominent leaders in medicine and healthcare, to Chicago’s McCormick Place. More...
Six hundred fifty exhibitors will also introduce more than 200 new diagnostic products, making this one of the 10 largest medical exhibitions in the US.

Mobile health: digital health guru Eric Topol, MD, will deliver the keynote lecture on how mobile technology and the internet are transforming healthcare. A symposium will cover how lab-on-a-chip technology can combat illegal designer drugs, and will look at two experimental technologies that could be the future of illicit drug testing: a point-of-care volumetric bar-chart chip and a miniaturized mass spectrometry device.

Big data: Monday’s plenary speaker Viktor Mayer-Schönberger, coauthor of Big Data: A Revolution That Will Transform How We Live, Work, and Think, will explore how the medical world can harness the massive amounts of data generated by genomic, proteomic, and metabolomic analyses to create new diagnostic tests and disease treatments.

Infectious diseases: The World Health Organization (WHO; Geneva, Switzerland) found that microbial drug resistance has become a serious public health threat worldwide. This is a troubling trend that the short course “Hot Topics in Clinical Microbiology” will examine. Two other sessions will also focus on MALDI-TOF MS, a rising diagnostic technology that is poised to replace standard infectious disease testing techniques—some of which date back to the 1800s—and that could become an important weapon in the fight against antimicrobial resistance.

Diagnostic innovations: from smart phone-based diagnostic readers, to biochips with the potential to diagnose human immunodeficiency virus (HIV), to the first human papilloma virus (HPV) test approved for primary cervical cancer screening. The latest diagnostic technology in mobile health, infectious diseases, reproductive health, and more will also be displayed at the AACC Clinical Lab Expo.

At the 2014 AACC Annual Meeting & Clinical Lab Expo plenary sessions feature expert presentations on how mobile technology and the internet are revolutionizing healthcare, the importance of newborn screening, big data, the biologic basis of obesity, and the latest advances that could lead to a cure for HIV. Six hundred and fifty exhibitors will be demonstrating displays of the latest diagnostic their technologies, including but not limited to automation, information systems, point-of-care (POC), and biotech.

Related Links:
World Health Organization
American Association of Clinical Chemistry




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.